Chlorogenic acid compound and compounded stranguria-treating and calculus-removing tablet including same
The invention relates to a chlorogenic acid compound and a compounded stranguria-treating and calculus-removing tablet including the same. 2[theta] angles of characteristic peaks in an X-ray diffraction pattern acquired by performing Cu-K[alpha] ray measurement on the chlorogenic acid compound compr...
Gespeichert in:
Hauptverfasser: | , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to a chlorogenic acid compound and a compounded stranguria-treating and calculus-removing tablet including the same. 2[theta] angles of characteristic peaks in an X-ray diffraction pattern acquired by performing Cu-K[alpha] ray measurement on the chlorogenic acid compound comprise 4.6+/-0.2 degrees, 16.2+/-0.2degrees, 17.7+/-0.2degrees, 18.4+/-0.2degrees, 19.7+/-0.2degrees, 20.5+/-0.2degrees, 21.6+/-0.2degrees, 22.8+/-0.2degrees, 25.6+/-0.2degrees, 26.1+/-0.2degrees and 30.7+/-0.2degrees. The invention also relates to the compounded stranguria-treating and calculus-removing tablet including the compound and a preparation method thereof. The compounded tablet comprises the chlorogenic acid compound, so that bioavailability is significantly enhanced, and the compounded tablet has excellent effects of discharging calculi, diuresis, easing pain and diminishing inflammation.
本发明涉及种绿原酸化合物及含有该化合物的复方石淋通片。所述的绿原酸化合物使用Cu-Kα射线测量得到的X-射线衍射图中特征峰的2θ角包括4.6±0.2°、16.2±0.2°、17.7±0.2°、18.4±0.2°、19.7±0.2°、20. |
---|